Download presentation
Presentation is loading. Please wait.
Published byKerry McBride Modified over 5 years ago
1
Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats
Reiner Wiest, Ming–Hung Tsai, Roberto J. Groszmann Gastroenterology Volume 120, Issue 4, Pages (March 2001) DOI: /gast Copyright © 2001 American Gastroenterological Association Terms and Conditions
2
Fig. 1 Representative tracings for the effect of octreotide in the absence and presence of vasoconstrictors in PVL rats. Arrows indicate time points of bolus application of octreotide, given in increasing doses (−8 to −3.5 [log10] mol/L or 0.001, 0.01, 0.1, 0.5, 1, 5, 10, and 50 μg). (A) At baseline conditions (without vasoconstrictor), octreotide did not induce any effect on perfusion pressure. (B) After preconstriction of mesenteric preparations with KCl, octreotide showed no effect. (C) However, after preconstriction with the α1-adrenergic agonist MT, (D) ET-1, and (E) the PKC-activator PdBU, octreotide did facilitate the preexisting vasoconstriction and increased perfusion pressure dose-dependently. Gastroenterology , DOI: ( /gast ) Copyright © 2001 American Gastroenterological Association Terms and Conditions
3
Fig. 2 Vasoconstrictive effect of octreotide: dependency on NO and endothelium. For PVL (■) and sham (●) animals, cumulative dose-response curves for octreotide in the presence of MT were obtained (A) in untreated mesenteric preparations, (B) after inhibition of NO formation, and (C) after removal of the endothelium. Note the higher dose-response curves in mesenteric vasculature after NO blockade or after removal of the endothelium than in intact normal preparations. ANOVA, P < 0.05. Gastroenterology , DOI: ( /gast ) Copyright © 2001 American Gastroenterological Association Terms and Conditions
4
Fig. 3 Vasoconstrictive effect of octreotide depends on the type of vasoconstrictor present. Cumulative dose-response curves for octreotide in de-endothelialized mesenteric vasculature after preconstriction with (A) ET-1 (2 nmol/L), (B) PdBU (20 μmol/L). ●, PVL; ○, sham. Gastroenterology , DOI: ( /gast ) Copyright © 2001 American Gastroenterological Association Terms and Conditions
5
Fig. 4 Role of PKC, PLA2, and COX in the vasoconstrictive effect of octreotide. Cumulative dose-response curves for octreotide in de-endothelialized mesenteric vasculature in the presence and absence of (A) calphostin C (specific PKC inhibitor), (B) quinacrine (nonselective PLA2 inhibitor), and (C) indomethacin (COX inhibitor). Note that the blocking agents completely suppressed the amplification of α1-adrenergic vascular smooth muscle contraction induced by octreotide under normal conditions. Gastroenterology , DOI: ( /gast ) Copyright © 2001 American Gastroenterological Association Terms and Conditions
6
Fig. 5 Proposed mechanism for the potentiation of local vasoconstriction in mesenteric vascular smooth muscle by octreotide. After binding of the α1-adrenergic agonist (MT) or ET-1 on their respective receptors, the activity of phospholipase C (PLC) is first stimulated. The formed 1,4,5-inositol triphosphate (IP3) opens Ca2+ channels on intracellular Ca2+ stores, increasing intracellular Ca2+ concentration, which is necessary for translocation and binding of PLA2 to membranes. Simultaneous formation of diacylglycerol (DAG) activates PKC, which by phosphorylation of a putative inhibitor (Inh.) allows PLA2 to be stimulated by octreotide. The released arachidonic acid enters the COX pathway, resulting in production of vasoconstrictive prostanoids and potentiation of vasoconstriction. AA, arachidonic acid; SSTR2, somatostatin receptor subtype 2. Modified and reprinted with permission.82 Gastroenterology , DOI: ( /gast ) Copyright © 2001 American Gastroenterological Association Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.